Damora Therapeutics, Inc. (DMRA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US36322Q2066
Damora Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -210.87 m USD |
| EBIT | -209.79 m USD |
| Net income | -209.84 m USD |
| Diluted EPS – continuing operations | 3.98 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
More stocks
- Yangling Metron New Material Co Ltd (300861.SZ)
- Hualan Biological Bacterin Inc. (301207.SZ)
- Lyntris Inc. (LYNX)
- Riskified Ltd (RSKD)
- Adient plc (ADNT)
- Shift Up Corporation (462870.KS)
- China Modern Dairy Holdings Ltd (1117.HK)
- Turning Point Brands, Inc. (TPB)
- Shenzhen SOFARSOLAR Co., Ltd. (301658.SZ)
- Kardigan, Inc. Common Stock (KARD)
- Tenaz Energy Corp (TNZ.TO)
- Wuhan Tianyuan Environmental Protection Co.LTD (301127.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.